One investigation discussed during the call involves sales reps in China allegedly changing genetic testing results to secure reimbursement for Tagrisso.

NEW YORK – Alentis Therapeutics on Tuesday announced that it has raised $181.4 million in a series D financing round, and that it will put the funds toward developing antibody-drug conjugates ...

A Phase I study of invikafusp alfa presented at SITC provided the rationale to enroll patients with TMB-high, MSI-high, and virus-associated tumors in Phase II.

NEW YORK – Neurogene on Monday said after the market closed that it will stop advancing NGN-101 as a treatment for CLN5 Batten disease, a very rare genetic disorder. The New York-based company said it ...

The firm will use the funding to support the Phase I trial of its CAR T-cell therapy, VIPER-101, in lymphoma patients.

Ideaya plans to submit an investigational new drug application next year for IDE034, a B7H3/PTK7 topo-I-payload bispecific antibody-drug conjugate.

The biomarker assay can be used potentially to enrich clinical trials and monitor patients' disease activity and treatment response.

NEW YORK – Canhelp Genomics on Monday said it is collaborating with Mirxes Singapore to provide solid tumor origin identification testing services in Singapore, Malaysia, Thailand, Indonesia, and the ...

A half-dozen hospital systems plan to implement the tool, which combs through patient medical records to identify those ...

Based on early Phase I/II trial data, Tango has decided to end enrollment in a study of TNG908 and focus resources on more promising drugs in its pipeline.

The agency reviewed data from the FELIX trial, in which 63 percent of patients achieved a complete remission on the cell therapy at any time point.

The partners are advancing a pipeline of engineered DNase I therapies designed to work with CAR T cells to kill tumor cells.